Format

Send to

Choose Destination
See comment in PubMed Commons below
J Child Adolesc Psychopharmacol. 2011 Feb;21(1):43-50. doi: 10.1089/cap.2010.0024.

Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures.

Author information

1
Department of Psychiatry, School of Medicine, University of Pittsburgh , Pittsburgh, PA 15203, USA. handenbl@upmc.edu

Abstract

OBJECTIVE:

There has been recent interest in the use of cognitive enhancing drugs, such as cholinesterase inhibitors, as a possible treatment for executive functioning (EF) deficits in autism spectrum disorder (ASD). The goal of this study was to assess the tolerability, safety, and efficacy of donepezil on EF in a sample of children and adolescents with ASD.

METHOD:

Thirty-four children and adolescents with ASD (age range 8-17 years; IQ >75) were enrolled in a 10-week, double-blind, placebo-controlled trial of donepezil (doses of 5 and 10 mg), followed by a 10-week open label trial for placebo nonresponders.

RESULTS:

The effect of donepezil treatment on EF was examined. Despite improvement on a number of EF measures, no statistically significant between-group differences were found (with gains observed for both the placebo and donepezil groups).

CONCLUSIONS:

The results suggest that short-term treatment with donepezil may have limited impact on cognitive functioning in ASD. Future controlled trials may need to consider a longer treatment period to detect significant gains on EF measures.

PMID:
21309696
PMCID:
PMC3037196
DOI:
10.1089/cap.2010.0024
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Mary Ann Liebert, Inc. Icon for PubMed Central
    Loading ...
    Support Center